PCRX
Pacira BioSciences Inc

1,571
Mkt Cap
$824.29M
Volume
1.89M
52W High
$27.64
52W Low
$18.92
PE Ratio
42.95
PCRX Fundamentals
Price
$19.16
Prev Close
$20.65
Open
$20.51
50D MA
$24.26
Beta
0.38
Avg. Volume
834,880.77
EPS (Annual)
-$2.15
P/B
1.13
Rev/Employee
$887,298.73
Loading...
Loading...
News
all
press releases
Pacira BioSciences (NASDAQ:PCRX) Hits New 52-Week Low - Time to Sell?
Pacira BioSciences (NASDAQ:PCRX) Reaches New 12-Month Low - Time to Sell...
MarketBeat·3d ago
News Placeholder
More News
News Placeholder
Do Options Traders Know Something About Pacira BioSciences Stock We Don't?
Investors need to pay close attention to PCRX stock based on the movements in the options market lately.
Zacks·3d ago
News Placeholder
Pacira BioSciences (NASDAQ:PCRX) Shares Down 6.9% - What's Next?
Pacira BioSciences (NASDAQ:PCRX) Stock Price Down 6.9% - Time to Sell...
MarketBeat·4d ago
News Placeholder
PCRX, LG Chem Partner to Expand Exparel Reach Across the Asia-Pacific
Pacira BioSciences teams up with LG Chem to expand Exparel across Asia-Pacific, unlocking royalties and new revenue channels to support international growth.
Zacks·5d ago
News Placeholder
PCRX Stock Down 10% as Preliminary Q4 Revenues Miss Estimates
Pacira BioSciences stock slides nearly 10% after preliminary Q4 revenues of $196.9 million miss estimates, despite Exparel sales topping forecasts.
Zacks·7d ago
News Placeholder
Lauren Riker Sells 1,416 Shares of Pacira BioSciences (NASDAQ:PCRX) Stock
Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) SVP Lauren Riker sold 1,416 shares of the business's stock in a transaction dated Monday, January 5th. The stock was sold at an average price...
MarketBeat·13d ago
News Placeholder
Pacira BioSciences, Inc. (NASDAQ:PCRX) Receives Average Recommendation of "Hold" from Analysts
Shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Get Free Report) have received a consensus rating of "Hold" from the seven research firms that are presently covering the firm, MarketBeat.com...
MarketBeat·15d ago
News Placeholder
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc.
DOMA Perpetual Capital Management Announces Intent to Nominate Three Highly Qualified, Independent Director Candidates at 2026 Annual Meeting of Pacira BioSciences, Inc. DOMA Perpetual Capital...
PR Newswire·20d ago
News Placeholder
Pacira BioSciences, Inc. $PCRX Shares Sold by Simplify Asset Management Inc.
Simplify Asset Management Inc. lessened its stake in Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 62.8% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned...
MarketBeat·20d ago
News Placeholder
Pacer Advisors Inc. Trims Position in Pacira BioSciences, Inc. $PCRX
Pacer Advisors Inc. decreased its position in shares of Pacira BioSciences, Inc. (NASDAQ:PCRX - Free Report) by 48.2% during the 3rd quarter, according to the company in its most recent 13F filing...
MarketBeat·20d ago
<
1
2
...
>

Latest PCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.